CD274 and neoplasm: The phase III open-label KEYNOTE-045 trial of patients with advanced UC that recurred or progressed after platinum-based chemotherapy demonstrated that pembrolizumab monotherapy significantly improved median OS in the total population (10.3 vs. 7.4 months; HR, 0.73; 95% CI, 0.59–0.91; P = 0.002) and in patients who had a PD-L1–positive (CPS ≥ 10) tumour (8.0 vs. 5.2 months; HR, 0.57; 95% CI, 0.37–0.88; P = 0.005) compared with the investigator’s choice of chemotherapy with paclitaxel, docetaxel, or vinflunine (116).